4.5 Article

Secondary prevention in diabetic and nondiabetic coronary heart disease patients: Insights from the German subset of the hospital arm of the EUROASPIRE IV and V surveys

期刊

CLINICAL RESEARCH IN CARDIOLOGY
卷 -, 期 -, 页码 -

出版社

SPRINGER HEIDELBERG
DOI: 10.1007/s00392-022-02093-0

关键词

Coronary heart disease; Diabetes Mellitus; Secondary Prevention; EUROASPIRE

资金

  1. German Ministry of Education and Research (BMBF) within the Comprehensive Heart Failure Center Wurzburg [BMBF 01EO1004]
  2. German Heart Foundation
  3. Amarin
  4. Amgen
  5. Daiichi Sankyo
  6. Eli Lilly
  7. Pfizer
  8. Sanofi
  9. Ferrer
  10. Novo Nordisk
  11. Astra-Zeneca
  12. Bristol-Myers Squibb/Emea Sarl
  13. GlaxoSmithKline
  14. F Hoffman-La Roche
  15. Merck and Sharp Dohme
  16. Projekt DEAL

向作者/读者索取更多资源

This study compared the prevalence of cardiovascular risk factors and its determinants among chronic coronary heart disease patients in Germany between 2012 and 2017. The results showed that there were no significant differences in risk factor prevalence and lifestyle changes, except for lower LDL cholesterol levels in the later study period. The study suggests that stronger efforts towards lifestyle interventions and cardiac rehabilitation may help improve risk factor profiles in chronic CHD patients.
Background Patients with coronary heart disease (CHD) with and without diabetes mellitus have an increased risk of recurrent events requiring multifactorial secondary prevention of cardiovascular risk factors. We compared prevalences of cardiovascular risk factors and its determinants including lifestyle, pharmacotherapy and diabetes mellitus among patients with chronic CHD examined within the fourth and fifth EUROASPIRE surveys (EA-IV, 2012-13; and EA-V, 2016-17) in Germany. Methods The EA initiative iteratively conducts European-wide multicenter surveys investigating the quality of secondary prevention in chronic CHD patients aged 18 to 79 years. The data collection in Germany was performed during a comprehensive baseline visit at study centers in Wurzburg (EA-IV, EA-V), Halle (EA-V), and Tubingen (EA-V). Results 384 EA-V participants (median age 69.0 years, 81.3% male) and 536 EA-IV participants (median age 68.7 years, 82.3% male) were examined. Comparing EA-IV and EA-V, no relevant differences in risk factor prevalence and lifestyle changes were observed with the exception of lower LDL cholesterol levels in EA-V. Prevalence of unrecognized diabetes was significantly lower in EA-V as compared to EA-IV (11.8% vs. 19.6%) while the proportion of prediabetes was similarly high in the remaining population (62.1% vs. 61.0%). Conclusion Between 2012 and 2017, a modest decrease in LDL cholesterol levels was observed, while no differences in blood pressure control and body weight were apparent in chronic CHD patients in Germany. Although the prevalence of unrecognized diabetes decreased in the later study period, the proportion of normoglycemic patients was low. As pharmacotherapy appeared fairly well implemented, stronger efforts towards lifestyle interventions, mental health programs and cardiac rehabilitation might help to improve risk factor profiles in chronic CHD patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据